LRMR
NASDAQ · Biotechnology
Larimar Therapeutics Inc
$4.73
+0.23 (+5.11%)
Open$4.64
Previous Close$4.50
Day High$4.82
Day Low$4.58
52W High$6.42
52W Low$1.61
Volume—
Avg Volume2.36M
Market Cap503.83M
P/E Ratio—
EPS$-2.21
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+392.0% upside
Current
$4.73
$4.73
Target
$23.27
$23.27
$16.60
$23.27 avg
$30.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 175.11M | 171.92M | 184.32M |
| Net Income | -19,494,630 | -18,016,562 | -21,970,966 |
| Profit Margin | -11.1% | -10.5% | -11.9% |
| EBITDA | -28,814,403 | -28,168,357 | -29,490,113 |
| Free Cash Flow | -20,989,250 | -18,411,143 | -19,560,158 |
| Rev Growth | -5.1% | +17.2% | +14.9% |
| Debt/Equity | 0.69 | 0.58 | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |